Congressional Republicans are facing pressure to find ways to save money in their budget reconciliation package, with a focus on Medicaid spending. However, instead of addressing the underlying issues driving the program’s unsustainability, the Trump administration is pushing for a “most favored nation” (MFN) policy on drug pricing.
The MFN policy aims to align Medicaid reimbursement rates with the prices paid for prescription drugs in other developed countries. These prices are typically lower due to price controls implemented by foreign governments. While this may seem like a straightforward cost-saving measure, it is merely a short-term solution that could have long-lasting negative consequences on the healthcare system.
One of the key concerns with the MFN policy is its potential impact on the 340B drug discount program. Originally created to help hospitals and clinics serving low-income populations access discounted medications, the program has evolved into a profit center for larger health systems. These hospitals often purchase drugs at a discount through 340B and then resell them at full price to Medicare or privately insured patients, pocketing the price difference.
Under the MFN policy, Medicaid prices would fall, leading to deeper discounts through the 340B program. This would result in manufacturers facing significant losses, which could prompt them to raise prices in the commercial market. As a result, patients, small businesses, and insurers could bear the brunt of these increased costs.
Furthermore, the MFN policy could jeopardize drug access and innovation. Manufacturers are already required to offer steep rebates through Medicaid and 340B to access Medicare Part B coverage. With Medicaid discounts already exceeding 50% on average, the MFN policy could further drive down prices, potentially leading manufacturers to exit the market altogether. This could limit patient access to treatments and hinder investment in new drug development.
Instead of relying on the MFN policy, there are better alternatives for generating savings in Medicaid. Ideas such as block grants, per-capita caps, stricter eligibility verification, and adjusting the federal match rate for different populations could help restore fiscal stability without compromising innovation or rewarding market manipulation.
In conclusion, the MFN policy reinforces negative incentives in the 340B program, shifts costs onto patients and employers, and poses a threat to the long-term health of public programs and private enterprise. It is crucial to consider alternative reforms that address the root causes of Medicaid’s financial challenges without jeopardizing innovation and patient access to essential medications.
